Whipplewood Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Whipplewood Advisors's BMY Position: Q1 2026 in Review
Whipplewood Advisors reduced its Bristol-Myers Squibb (BMY) stake by 87% in Q1 2026, selling an estimated $64.1K and leaving 167 shares worth $10.1K. The position accounts for 0.01% of the portfolio, ranked #485.
Whipplewood Advisors first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $92.3K in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Whipplewood Advisors held 167 shares of Bristol-Myers Squibb worth $10.1K as of Q1 2026.
- Whipplewood Advisors sold 1,100 Bristol-Myers Squibb shares in Q1 2026, an estimated $64.1K.
- Bristol-Myers Squibb made up 0.01% of Whipplewood Advisors's portfolio in Q1 2026, its #485 holding.
- Whipplewood Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
- Whipplewood Advisors's Bristol-Myers Squibb position peaked at $92.3K in Q1 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Whipplewood Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.